Lunai Bioworks Inc.: Delisting notice
What happened
- Nasdaq determined Lunai Bioworks no longer meets the $2,500,000 stockholders’ equity requirement under Listing Rule 5550(b)(1).
- The company will not request a hearing and plans to voluntarily withdraw its common stock from Nasdaq listing.
- Nasdaq trading is expected to be suspended at the opening of business on October 30, 2026; no over-the-counter quotation is planned.
Why it matters
The delisting and planned suspension of SEC reporting may materially reduce liquidity, disclosure, and financing options for Lunai Bioworks and its investors. Corporate finance, restructuring, accounting, and ECM professionals should monitor the company’s transition and eligibility for Form 15.
What to watch. Trading suspension is expected October 30, 2026; Lunai intends to file Form 25 on or about November 2, 2026, with delisting expected on or about November 12, 2026. The company may later file Form 15 if eligible.
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 16William Anderson Wittekind discloses a stake in Lunai Bioworks Inc. (amended)
- First reported by PR NewswireOct 22Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister
- 8-K current reportOct 23Lunai Bioworks Inc.: Delisting notice
Who is involved
Sources (2)
Related
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.